SEC Form 4 · accession 0001209191-15-049854
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Benevich
Officer — Chief Commercial Officer
Period of report
Jun 1, 2015
Accepted (ET)
Jun 3, 2015 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $41.78 | Jun 1, 2015 | A | 60,000 | A | Jun 1, 2016 | Jun 1, 2025 | Common Stock | 60,000 | 60,000 | D |
| Restricted Stock UnitF2,F3 | — | Jun 1, 2015 | A | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Option was granted June 1, 2015 and vests at 25% upon first anniversary (June 1, 2016) and remaining 75% vesting in 36 equal monthly installments beginning July 1, 2016.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F3The Restricted Stock Unit will vest on June 1, 2018, subject to continued service to the Company.